Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biogen Inc. (BIIB)
Price$226.88Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | $6.93B | $5.52B | $5.05B | $4.72B | $4.38B | $4.10B | $3.17B |
| Gross profit | $7.49B | $7.37B | $7.30B | $7.90B | $8.87B | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B | $9.52B | $8.53B | $6.07B | $4.97B | $4.58B | $4.32B | $4.00B | $3.70B | $2.84B |
| Gross margin | 75.69% | 76.12% | 74.24% | 77.61% | 80.79% | 86.57% | 86.40% | 86.50% | 86.72% | 87.08% | 88.48% | 87.93% | 87.63% | 90.11% | 90.76% | 91.51% | 91.27% | 90.19% | 89.43% |
| Research & development | $1.78B | $1.98B | $2.45B | $2.23B | $2.50B | $3.99B | $2.28B | $2.60B | $2.25B | $1.97B | $2.01B | $1.89B | $1.44B | $1.33B | $1.22B | $1.25B | $1.28B | $1.07B | $925.2M |
| Operating expenses | $8.33B | $7.77B | $8.54B | $6.58B | $8.14B | $8.89B | $7.34B | $7.56B | $6.93B | $6.30B | $5.87B | $5.75B | $3.56B | $3.12B | $3.32B | $3.47B | $3.08B | $2.88B | $2.39B |
| Operating income | $1.56B | $1.91B | $1.30B | $3.59B | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B | $4.89B | $3.97B | $2.52B | $1.86B | $1.72B | $1.25B | $1.30B | $1.21B | $779.8M |
| Operating margin | 15.74% | 19.70% | 13.18% | 35.31% | 25.87% | 33.84% | 48.98% | 43.77% | 43.55% | 45.00% | 45.44% | 40.94% | 36.29% | 33.64% | 34.16% | 26.48% | 29.59% | 29.62% | 24.59% |
| EBITDA | $2.34B | $2.58B | $1.79B | $4.11B | $3.33B | $5.01B | $7.51B | $6.54B | $6.43B | $5.83B | $5.49B | $4.66B | $3.05B | $2.22B | $2.08B | $1.60B | $1.72B | $1.68B | $1.16B |
| EBITDA margin | 23.62% | 26.66% | 18.22% | 40.40% | 30.31% | 37.24% | 52.21% | 48.61% | 52.36% | 50.96% | 51.02% | 48.03% | 43.96% | 40.27% | 41.27% | 34.02% | 39.37% | 40.89% | 36.58% |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | $1.86B | $1.38B | $1.23B | $1.01B | $970.1M | $783.2M | $638.2M |
| Net profit margin | 13.07% | 16.87% | 11.81% | 29.95% | 14.17% | 29.76% | 40.96% | 32.93% | 20.69% | 32.34% | 32.95% | 30.25% | 26.86% | 25.02% | 24.45% | 21.31% | 22.16% | 19.11% | 20.12% |
| Basic EPSper basic share | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.63 | $11.94 | $16.96 | $15.38 | $12.42 | $7.86 | $5.80 | $5.09 | $3.98 | $3.37 | $2.67 | $2.02 |
| Diluted EPSper diluted share | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | $7.81 | $5.76 | $5.04 | $3.94 | $3.35 | $2.65 | $1.99 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
FMR LLC | 18.22M |
BlackRock, Inc. | 15.99M |
PRIMECAP MANAGEMENT CO/CA/ | 15.15M |
VANGUARD CAPITAL MANAGEMENT LLC | 9.65M |
STATE STREET CORP | 7.34M |
VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6M |
GEODE CAPITAL MANAGEMENT, LLC | 4.45M |
WELLINGTON MANAGEMENT GROUP LLP | 3.12M |
NORGES BANK | 2.58M |
MORGAN STANLEY | 2.41M |
AQR CAPITAL MANAGEMENT LLC | 1.94M |
JPMORGAN CHASE & CO | 1.82M |
Invesco Ltd. | 1.8M |
Amundi | 1.52M |
Legal & General Group Plc | 1.49M |
NORTHERN TRUST CORP | 1.43M |
Boston Partners | 1.26M |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.26M |
GOLDMAN SACHS GROUP INC | 1.23M |
DIMENSIONAL FUND ADVISORS LP | 1.15M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 12, 2026Form 4 | Murphy NicoleHead of Pharm Ops and Tech | BuyCommon Stock | 3 | $195.04 | $585.12 | 19.6K |
| Feb 9, 2026Form 4 · 10b5-1 | Singhal PriyaHead of Development | SellCommon Stock | 2.7K | $199.83 | $531.5K | 8.0K |
| Feb 2, 2026Form 4 · 10b5-1 | Singhal PriyaHead of Development | SellCommon Stock | 748 | $179.30 | $134.1K | 6.3K |
| Sep 2, 2025Form 4 · 10b5-1 | Singhal PriyaHead of Development | SellCommon Stock | 517 | $133.55 | $69.0K | 5.8K |
| Jul 8, 2025Form 4 · 10b5-1 | Izzar RachidHead of Global Product Strat. | SellCommon Stock | 2.2K | $135.00 | $300.1K | 6.3K |
Community posts
Biogen and Eisai win Japanese approval for Leqembi injection pen
Biogen ($BIIB) and Eisai received Japanese approval for Leqembi Pen, a subcutaneous formulation of their treatment for early Alzheimer’s disease. The regimen uses two pens totaling 500 milligrams once weekly, offering an alternative to intr ...
